# Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

> **NCT05148546** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 69 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant nivolumab
- **DRUG:** Neoadjuvant ipilimumab
- **DRUG:** Neoadjuvant relatlimab

## Key facts

- **NCT ID:** NCT05148546
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-28
- **Primary completion:** 2025-04-22
- **Final completion:** 2029-04
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05148546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05148546, "Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05148546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*